MG
BCRX icon

Mather Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Mather Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-355
Closed -$2.69K – 750
2025
Q3 		$2.69K Buy
+355
New +$2.96K ﹤0.01% 1500
2025
Q2 		– Sell
-355
Closed -$2.66K – 718
2025
Q1 		$2.66K Buy
+355
New +$2.86K ﹤0.01% 1525
2024
Q3 		– Sell
-355
Closed -$1.8K – 1758
2024
Q2 		$1.8K Buy
355
+155
+78% +$855 ﹤0.01% 1913
2024
Q1 		$1.2K Buy
+200
New +$1.13K ﹤0.01% 1605

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mather Group's BCRX Position: Q4 2025 in Review

Mather Group sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 355 shares — an estimated $2.69K sold.

Mather Group first reported a position in BCRX in Q1 2024 and held it in 4 quarters. The position peaked at $2.69K in Q3 2025. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Mather Group reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Mather Group sold 355 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $2.69K.
  • Mather Group first reported a position in BioCryst Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Mather Group's BioCryst Pharmaceuticals position peaked at $2.69K in Q3 2025.
  • 272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Mather Group's 13F filing for Q4 2025, filed 13 Jan 2026.